Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.

David J Pinato | Anu Vallipuram | Joanne S Evans | Clement Wong | Hua Zhang | Matthew Brown | Roberto E Dina | Pritesh Trivedi | Ayse U Akarca | Teresa Marafioti | Francesco A Mauri | Rohini Sharma
Neuroendocrinology | 2021

A comprehensive characterization of the tumour microenvironment is lacking in neuroendocrine tumours (NETs), where programmed cell death-1 receptor-ligand (PD-1/PD-L1) inhibitors are undergoing efficacy testing.

Pubmed ID: 32097935

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Associated grants

  • Agency: Department of Health, United Kingdom
  • Agency: Wellcome Trust, United Kingdom
    Id: PS3416

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Human B7-H1 Phycoerythrin MAb (Clone 130021) (antibody)

RRID:AB_10971948

This monoclonal targets Human B7-H1 Phycoerythrin MAb (Clone 130021)

View all literature mentions